← Leaderboards
Charles Bix Shoemaker
Tufts University Boston
$9,649,281
Attributed
$16,166,069
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,166,069 · 10
By mechanism
R01$11,665,642 · 4
U54$2,250,459 · 1
R21$2,249,968 · 5
Top collaborators
- Rongsheng Jin8 shared
- George A. Oyler5 shared
- Saul R Tzipori3 shared
- David T Curiel2 shared
- Sanjay Ram2 shared
- Patrick J Skelly2 shared
Most similar at Tufts University Boston
Same institution · by research overlap
- Saul R Tzipori$24,857,188
- Jennifer A. Steele$97,850
- Paola Massari$2,778,263
- Donna E Akiyoshi$1,949,457
- Joe Sorg$9,025,831
Others in their field
Top investigators on “Toxin”
- Jacqueline Moline · Icahn School Of Medicine At Mount Sinai$75,762,106
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$75,392,927
- Alessandro Sette · La Jolla Institute For Immunology$39,651,711
- Milan Tomic · Xoma Corporation$38,826,613
- Jon Mirsalis · Sri International$38,701,962
- Robert H Vonderheide · University Of Pennsylvania$33,448,494
Research focus
ToxinProteinsIntoxicationMediatingPreventTherapeutic AgentsSerotypingBaseSerumBontoxilysinAffinitySpecificityInfectionRecombinantsLeadTechnologyBotulismBiodefensePropertyInnovationBotulinum Toxin Type ALinkAnimalsDesign
Grant awards (31)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents$1,549,397
R01 · FY2025 · AI · contact PI
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents$802,815
R01 · FY2024 · AI · contact PI
Development of nanobody immunotherapeutics that prevent and treat gonorrhea$208,392
R21 · FY2024 · AI
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes$206,250
R21 · FY2024 · AI
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents$865,682
R01 · FY2023 · AI · contact PI
Immune-based therapy against STEC intoxication and HUS$466,864
R01 · FY2023 · AI
Development of nanobody immunotherapeutics that prevent and treat gonorrhea$265,676
R21 · FY2023 · AI
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes$247,500
R21 · FY2023 · AI
Immune-based therapy against STEC intoxication and HUS$463,531
R01 · FY2022 · AI
Immune-based therapy against STEC intoxication and HUS$472,682
R01 · FY2021 · AI
Molecular mechanisms of botulinum neurotoxin neutralization$567,527
R01 · FY2020 · AI
Molecular mechanisms of botulinum neurotoxin neutralization$577,448
R01 · FY2019 · AI
Molecular mechanisms of botulinum neurotoxin neutralization$587,371
R01 · FY2018 · AI
Molecular mechanisms of botulinum neurotoxin neutralization$597,917
R01 · FY2017 · AI
Molecular mechanisms of botulinum neurotoxin neutralization$636,248
R01 · FY2016 · AI
A platform for therapeutic agents that promote rapid recovery from botulism$859,639
R01 · FY2015 · AI · contact PI
A platform for therapeutic agents that promote rapid recovery from botulism$785,489
R01 · FY2014 · AI · contact PI
A platform for therapeutic agents that promote rapid recovery from botulism$738,360
R01 · FY2013 · AI · contact PI
Tagged binding agents as improved anti-toxin therapeutics$385,747
U54 · FY2013 · AI · contact PI
Motor neuron-targeted adenovirus antidotes for botulism$231,510
R21 · FY2013 · AI · contact PI
A platform for therapeutic agents that promote rapid recovery from botulism$834,310
R01 · FY2012 · AI · contact PI
Tagged binding agents as improved anti-toxin therapeutics$486,911
U54 · FY2012 · AI · contact PI
Motor neuron-targeted adenovirus antidotes for botulism$208,606
R21 · FY2012 · AI · contact PI
A platform for therapeutic agents that promote rapid recovery from botulism$860,362
R01 · FY2011 · AI · contact PI
Tagged binding agents as improved anti-toxin therapeutics$461,038
U54 · FY2011 · AI · contact PI
Reversing botulism with agents that accelerate intraneuronal toxin degradation$236,099
R21 · FY2011 · AI · contact PI
Tagged binding agents as improved anti-toxin therapeutics$482,132
U54 · FY2010 · AI · contact PI
Reversing botulism with agents that accelerate intraneuronal toxin degradation$210,060
R21 · FY2010 · AI · contact PI
Tagged binding agents as improved anti-toxin therapeutics$434,631
U54 · FY2009 · AI · contact PI
In vivo panning for schistosome protective epitopes$198,125
R21 · FY2005 · AI
In vivo panning for schistosome protective epitopes$237,750
R21 · FY2004 · AI